Shares of Inovio Pharmaceuticals (NASDAQ: INO) saw a decline in the stock market, marking two consecutive sessions of losses on NASDAQ. Falling 9.11% to $12.47 as of 12:38 EST Monday morning, these losses took place even as NASDAQ itself experienced an upward movement of 0.21% to $15,062.46.
Prior Performance of Inovio Pharmaceuticals
Inovio Pharmaceuticals ended their last session at $12.52, which is considerably underperforming their 52-week high of $33.82. This company is a Pennsylvania-based biotechnology firm that specializes in developing DNA medicines for treating human papillomavirus (HPV), cancer, and infectious diseases. Currently, they are developing various treatments targeted at conditions related to HPV like cervical high-grade dysplasia, recurrent respiratory papillomatosis and glioblastoma multiforme.
Financial Status of Inovio Pharmaceuticals
Despite falling prices, Inovio Pharmaceuticals managed an earnings per share (EPS) of 1.04 over the past twelve months. However, their return on equity, measuring profitability in relation to shareholders’ equity, was a disappointing negative 87.1% for the same period.
Further Underperformance and Future Predictions
Evidence of Inovio’s underperformance can be seen in its recent sales growth which was negative in this quarter (-66.8%), and is predicted to continue in the same vein for the subsequent quarters (-58.11%). Moreover, Inovio Pharmaceuticals’ stock has reached an overbought condition, according to its stochastic oscillator, likely indicating a pending correction in price.
Volatility of Inovio Pharmaceuticals’ Stock
The stock has experienced various degrees of volatility, with a negative change of 1.23% in the last week, a slight positive change of 0.95% in the prior month, and a considerable positive return of 4.28% from quarter to quarter. Given this fluctuation, investors are advised to carefully consider these aspects before making investment decisions involving this particular stock.
More news about Inovio Pharmaceuticals (INO).
